2020–2021 Board of Directors Installed at 2020 ISPE Annual Meeting & Expo

ISPE installed its 2020–2021 International Board of Directors during the virtual 2020 ISPE Annual Meeting & Expo, revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors. The Board is responsible for the governance and strategic direction of the Society.

The following pharmaceutical industry leaders have been elected to the 2020–2021 ISPE International Board of Directors:

2020-2021 ISPE International Board of Directors

Officers

Chair

Vice Chair

Treasurer

Secretary

Past Chair

Directors Elected to a Second Term

Vivianne J. Arencibia

Vice President, Global Quality Systems and Compliance

Moderna

Chris Chen, PhD

CEO

WuXi Biologics (Shanghai) Co., Ltd.

New Directors:

Nina S. Cauchon, PhD

Director Regulatory Affairs - CMC

Amgen Inc.

Board Appointed Director

Founder & CEO

LifeBee - Digitalizing Life Sciences

Hirofumi Suzuki, PhD

Product Supply Japan, Head of Product Supply Coordination

Bayer Yakuhin Ltd.

Continuing Board Members

In addition to those named above, the following Directors were elected in 2019 to serve a two-year term and will continue their service on the Board:

Ylva Ek

Founder

Robur Life Science Advisory AB

CEO and Owner

Nephron Pharmaceuticals

Stephen Mahoney

Executive Director, Head of Quality Policy and Advocacy

Gilead Sciences

Alice Redmond, PhD

Chief Strategy Officer

CAI

Young Professionals Representative (Ex Officio)

Board Young Professionals Representative (Non-voting)

Explore the ISPE Board of Directors webpage for complete biographical information on all of ISPE's International Board.